Hvivo (HVO) RNS Announcements

Add to Alert list
Date Time Source Announcement
20 Mar 2020 02:06 PM
RNS
Second Price Monitoring Extn
20 Mar 2020 02:00 PM
RNS
Price Monitoring Extension
16 Mar 2020 07:00 AM
RNS
Publication of positive results in journal
12 Mar 2020 03:32 PM
RNS
Holding(s) in Company
12 Mar 2020 09:00 AM
RNS
Holding(s) in Company
10 Mar 2020 07:00 AM
RNS
Publication of Positive Results in Journal
09 Mar 2020 04:53 PM
RNS
Completion of Compulsory Acquisition of Shares
09 Mar 2020 07:00 AM
RNS
Coronavirus Challenge Study Model
06 Mar 2020 07:00 AM
RNS
New Contract
02 Mar 2020 03:25 PM
RNS
Change in Registered Office
27 Feb 2020 07:00 AM
RNS
Appointment of new Director
26 Feb 2020 03:04 PM
RNS
Result of Rule 15 Offer and Total Voting Rights
21 Feb 2020 07:00 AM
RNS
Investor Event Attendance and Presentation
20 Feb 2020 07:00 AM
RNS
Appointment of Chair of Advisory Board
13 Feb 2020 07:00 AM
RNS
Appointment of Group Chief Financial Officer
10 Feb 2020 11:17 AM
RNS
Value the Markets Webinar
07 Feb 2020 06:08 PM
RNS
Holding(s) in Company
07 Feb 2020 03:42 PM
RNS
Significant shareholder
07 Feb 2020 07:00 AM
RNS
Investor Event Attendance and Presentation
06 Feb 2020 09:30 AM
RNS
Total Voting Rights
06 Feb 2020 07:00 AM
RNS
Upcoming Investor Events
05 Feb 2020 11:00 AM
RNS
Exercise of Warrants and Issue of Shares
03 Feb 2020 10:30 AM
RNS
New Corporate Presentation
31 Jan 2020 11:23 AM
RNS
Results of Placing and Subscription
31 Jan 2020 07:00 AM
RNS
Proposed Placing to raise a minimum of £5 million
29 Jan 2020 04:43 PM
RNS
Holding(s) in Company
28 Jan 2020 07:00 AM
RNS
Compulsory Acquisition of Remaining hVIVO Shares
27 Jan 2020 03:00 PM
RNS
Holding(s) in Company
23 Jan 2020 07:00 AM
RNS
Update on Placing
22 Jan 2020 09:58 AM
RNS
Holding(s) in Company
22 Jan 2020 09:48 AM
RNS
Holding(s) in Company
21 Jan 2020 02:07 PM
RNS
Holding(s) in Company
20 Jan 2020 04:28 PM
RNS
Holding(s) in Company
20 Jan 2020 07:00 AM
RNS
Completion of Merger with hVIVO and Re-Admission
17 Jan 2020 08:01 AM
RNS
Rule 2.9 Announcement
17 Jan 2020 07:00 AM
RNS
Offer Wholly Unconditional
16 Jan 2020 02:00 PM
RNS
Schedule One Update
15 Jan 2020 08:01 AM
RNS
Rule 2.9 Announcement
14 Jan 2020 07:00 AM
RNS
Second Closing of the Offer
13 Jan 2020 04:31 PM
RNS
Exercise of Share Options
13 Jan 2020 01:39 PM
RNS
Exercise of Share Options
13 Jan 2020 09:00 AM
RNS
Price Monitoring Extension
13 Jan 2020 08:01 AM
RNS
Rule 2.9 Announcement
09 Jan 2020 01:29 PM
RNS
Exercise of Share Options
08 Jan 2020 07:01 AM
RNS
Director's Dealings
08 Jan 2020 07:00 AM
RNS
Exercise of Share Options
07 Jan 2020 02:12 PM
RNS
Publication and Posting of Rule 15 Proposals
06 Jan 2020 04:48 PM
RNS
Proposed cancellation of trading on AIM
06 Jan 2020 01:17 PM
RNS
Result of General Meeting
06 Jan 2020 08:00 AM
RNS
Schedule One

hVIVO is a contract research organization that conducts human challenge clinical trials for respiratory and infectious disease vaccines and therapeutics:

hVIVO offers services such as challenge trials, assay development, field trial bio-logistics, cell based assays, molecular services, compound efficacy and VRM, and biomarker analysis.

Formerly known as Retroscreen, hVIVO was renamed in 2015 when it went public on the London Stock Exchange.

hVIVO has a portfolio of 11 human challenge models, with more models in development. Their portfolio includes models for influenza, respiratory syncytial virus, human rhinovirus, asthma, COPD, cough, malaria, COVID-19, and hMPV.

hVIVO share price launched at 33p in 2012.

UK 100

Latest directors dealings